levofloxacin has been researched along with Hepatopulmonary Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, K; Qiu, J; Wang, W; Zheng, S; Zhu, J | 1 |
| Amado, V; Gaio, E; Huang, W; Melo-Silva, CA; Rangel, L; Storck, R | 1 |
| Jia, CK; Liang, L; Wang, WB | 1 |
3 other study(ies) available for levofloxacin and Hepatopulmonary Syndrome
| Article | Year |
|---|---|
Tea polyphenols and Levofloxacin alleviate the lung injury of hepatopulmonary syndrome in common bile duct ligation rats through Endotoxin -TNF signaling.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bacterial Translocation; Camellia sinensis; Common Bile Duct; Disease Models, Animal; Endotoxins; Hepatopulmonary Syndrome; Levofloxacin; Ligation; Lung; Lung Injury; Male; Polyphenols; Protein Interaction Maps; Rats, Sprague-Dawley; Signal Transduction; Tumor Necrosis Factor-alpha | 2021 |
Levofloxacin decreased chest wall mechanical inhomogeneities and airway and vascular remodeling in rats with induced hepatopulmonary syndrome.
Topics: Airway Remodeling; Animals; Cholestasis; Disease Models, Animal; Hepatopulmonary Syndrome; Levofloxacin; Lung; Male; Membrane Proteins; Pulmonary Artery; Rats; Rats, Wistar; Respiratory Muscles; Statistics, Nonparametric; Thoracic Wall; Topoisomerase II Inhibitors | 2013 |
[Reduction of endotoxin may protect lung from injury in rats with hepatopulmonary syndrome].
Topics: Animals; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Endotoxins; Hepatopulmonary Syndrome; Levofloxacin; Lung; Male; Malondialdehyde; Ofloxacin; Portal Pressure; Random Allocation; Rats; Rats, Sprague-Dawley | 2007 |